Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | ||
| Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | Advanced or Metastatic Renal Cell Carcinoma (RCC). | Reimburse with clinical criteria and/or conditions | Complete | ||
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Biktarvy | bictegravir/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Breo Ellipta | fluticasone furoate/vilanterol | Asthma | Withdrawn | |||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 15, 2024